Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...

Amgen’s best-selling biosimilars are even surpassing other high-profile medicines in its branded portfolio, such as the targeted cancer drug Lumakras and newer drugs like Uplizna and Tavneos. That ...

Researchers at City of Hope conducted a Phase 3 clinical trial and discovered that combining two drugs—sotorasib and panitumumab—helped patients live longer without their disease getting worse.

In a new study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, small molecule KRAS G12C inhibitor sotorasib combined with monoclonal ...

Margaret and her husband, David, were able to travel to Mexico because a clinical trial drug called zoldonrasib successfully controlled her lung cancer, which had returned after treatment. Dr. Kathryn ...

Patients who have the more specific KRAS G12C mutation now have access to two new FDA-approved targeted drugs — Lumakras and Vectibix. For patients with metastatic colon cancer, next-generation ...